The BRCA1 c.5096G>A p.(Arg1699Gln) missense variant has been shown to have an intermediate risk for BC and OC compared to other PVs and specific clinical management guidelines have been published for this variant [58]. This evidence concerns the gene BRCA1 and breast cancer.